A data-driven approach to identify risk profiles and protective drugs in COVID-19.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
07 01 2021
Historique:
pubmed: 12 12 2020
medline: 22 12 2020
entrez: 11 12 2020
Statut: ppublish

Résumé

As the COVID-19 pandemic is spreading around the world, increasing evidence highlights the role of cardiometabolic risk factors in determining the susceptibility to the disease. The fragmented data collected during the initial emergency limited the possibility of investigating the effect of highly correlated covariates and of modeling the interplay between risk factors and medication. The present study is based on comprehensive monitoring of 576 COVID-19 patients. Different statistical approaches were applied to gain a comprehensive insight in terms of both the identification of risk factors and the analysis of dependency structure among clinical and demographic characteristics. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells by binding to the angiotensin-converting enzyme 2 (ACE2), but whether or not renin-angiotensin-aldosterone system inhibitors (RAASi) would be beneficial to COVID-19 cases remains controversial. The survival tree approach was applied to define a multilayer risk stratification and better profile patient survival with respect to drug regimens, showing a significant protective effect of RAASi with a reduced risk of in-hospital death. Bayesian networks were estimated, to uncover complex interrelationships and confounding effects. The results confirmed the role of RAASi in reducing the risk of death in COVID-19 patients. De novo treatment with RAASi in patients hospitalized with COVID-19 should be prospectively investigated in a randomized controlled trial to ascertain the extent of risk reduction for in-hospital death in COVID-19.

Identifiants

pubmed: 33303654
pii: 2016877118
doi: 10.1073/pnas.2016877118
pmc: PMC7817222
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0
Antiviral Agents 0
Protective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : ErratumIn
Type : AssociatedDataset

Informations de copyright

Copyright © 2021 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

Shock. 2016 Sep;46(3):239-48
pubmed: 27082314
N Engl J Med. 2020 Jun 18;382(25):2441-2448
pubmed: 32356628
Pharmacol Res. 2017 Nov;125(Pt A):21-38
pubmed: 28619367
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
JAMA Cardiol. 2020 Jul 1;5(7):825-830
pubmed: 32324209
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Nat Med. 2020 Aug;26(8):1224-1228
pubmed: 32427924
JAMA Cardiol. 2020 Sep 1;5(9):1020-1026
pubmed: 32936273
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Lancet. 2020 Jun 13;395(10240):1820
pubmed: 32511943
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Biometrics. 1992 Jun;48(2):411-25
pubmed: 1637970
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Kidney Int. 1990 Jul;38(1):101-7
pubmed: 2200924
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
BMJ. 2020 May 14;369:m1844
pubmed: 32409486
Nature. 2020 Jun;582(7811):160
pubmed: 32504025
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
N Engl J Med. 2020 Jun 11;382(24):e92
pubmed: 32427428
Curr Atheroscler Rep. 2020 Aug 24;22(10):61
pubmed: 32830286
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Stat Med. 2004 Jan 15;23(1):77-91
pubmed: 14695641
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
J Perinatol. 2008 Dec;28 Suppl 3:S108-12
pubmed: 19057599

Auteurs

Pietro E Cippà (PE)

Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland; diserio.clelia@unisr.it Pietro.Cippa@eoc.ch.
Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.

Federica Cugnata (F)

University Centre of Statistics in the Biomedical Sciences, "Vita-Salute San Raffaele" University, 20132 Milan, Italy.

Paolo Ferrari (P)

Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Biomedical Faculty, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.

Chiara Brombin (C)

University Centre of Statistics in the Biomedical Sciences, "Vita-Salute San Raffaele" University, 20132 Milan, Italy.

Lorenzo Ruinelli (L)

ICT (Informatica e Tecnologia della Comunicazione), Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Giorgia Bianchi (G)

Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Nicola Beria (N)

Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Lukas Schulz (L)

Department of Medicine, Division of Nephrology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Enos Bernasconi (E)

Biomedical Faculty, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Department of Medicine, Division of Infectious Diseases, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.

Paolo Merlani (P)

Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
Department of Critical Care Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Alessandro Ceschi (A)

Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland.
Biomedical Faculty, Università della Svizzera Italiana, 6900 Lugano, Switzerland.
Institute of Pharmacology and Toxicology, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.

Clelia Di Serio (C)

University Centre of Statistics in the Biomedical Sciences, "Vita-Salute San Raffaele" University, 20132 Milan, Italy; diserio.clelia@unisr.it Pietro.Cippa@eoc.ch.
Biomedical Faculty, Università della Svizzera Italiana, 6900 Lugano, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH